-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $50

Benzinga·02/20/2026 18:00:25
Listen to the news
Wells Fargo analyst Yanan Zhu maintains Spyre Therapeutics (NASDAQ:SYRE) with a Overweight and raises the price target from $40 to $50.